Encompass Health (EHC) Financials

$119.47 -1.54 (-1.28%)

Closing price 05/28/2025 03:59 PM Eastern

Extended Trading

$119.46 -0.01 (-0.01%)

As of 08:02 AM Eastern

Annual Income Statements for Encompass Health

This table shows Encompass Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	456	352	271	412	284	359	375	271	248	182
Consolidated Net Income / (Loss)	597	463	366	517	369	446	292	271	248	183
Net Income / (Loss) Continuing Operations	599	475	351	403	278	446	374	351	318	254
Total Pre-Tax Income	750	607	451	505	353	562	493	496	482	396
Total Operating Income	865	732	630	659	528	693	630	649	649	547
Total Gross Profit	2,415	2,145	1,901	1,829	1,601	1,950	1,923	1,759	1,657	1,445
Total Revenue	5,373	4,801	4,349	4,015	3,566	4,605	4,277	3,914	3,643	3,163
Operating Revenue	5,373	4,801	4,349	4,015	3,566	4,605	4,277	3,914	3,643	3,163
Total Cost of Revenue	2,958	2,656	2,448	2,186	1,965	2,655	2,354	2,155	1,986	1,718
Operating Cost of Revenue	2,958	2,656	2,448	2,186	1,965	2,655	2,354	2,155	1,986	1,671
Total Operating Expenses	1,550	1,413	1,270	1,169	1,074	1,257	1,294	1,110	1,008	898
Selling, General & Admin Expense	1,251	1,139	1,027	950	868	1,039	964	853	764	697
Depreciation Expense	300	274	244	220	203	219	200	184	173	140
Total Other Income / (Expense), net	-115	-125	-179	-154	-175	-130	-136	-153	-167	-151
Interest Expense	138	144	177	165	186	167	147	165	180	165
Interest & Investment Income	3.00	3.20	2.90	3.40	2.90	6.70	8.70	8.00	9.80	8.70
Other Income / (Expense), net	20	16	-5.20	7.50	8.40	31	2.20	4.10	2.90	5.50
Income Tax Expense	150	132	100	102	75	116	119	146	164	142
Net Income / (Loss) Discontinued Operations	-2.80	-12	15	114	91	-0.60	1.10	-0.40	0.00	-0.90
Net Income / (Loss) Attributable to Noncontrolling Interest	141	111	95	105	85	87	-	-	-	-
Basic Earnings per Share	$4.53	$3.51	$2.72	$4.15	$2.87	$3.65	$2.98	$2.88	$2.77	$2.02
Weighted Average Basic Shares Outstanding	99.90M	99.50M	99.20M	99M	98.60M	98M	97.90M	93.70M	89.10M	89.40M
Diluted Earnings per Share	$4.46	$3.47	$2.70	$4.11	$2.85	$3.61	$2.93	$2.84	$2.59	$1.91
Weighted Average Diluted Shares Outstanding	102.20M	101.30M	100.40M	100.20M	99.80M	99.40M	99.80M	99.30M	99.50M	101M
Weighted Average Basic & Diluted Shares Outstanding	100.71M	100.14M	99.73M	99.44M	99.27M	98.43M	98.10M	99.30M	89.05M	89.78M
Cash Dividends to Common per Share	$0.64	$0.60	$0.86	$1.12	$1.12	$1.10	$1.04	$0.98	$0.94	$0.88

This table shows Encompass Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	152	121	108	114	113	88	85	91	88	89	45
Consolidated Net Income / (Loss)	197	164	147	147	139	119	113	117	113	139	45
Net Income / (Loss) Continuing Operations	197	164	148	148	140	128	115	118	114	119	86
Total Pre-Tax Income	239	201	184	186	178	165	145	151	146	151	107
Total Operating Income	267	232	209	216	208	190	179	184	179	180	148
Total Gross Profit	678	634	605	587	590	557	534	537	518	510	472
Total Revenue	1,455	1,405	1,351	1,301	1,316	1,247	1,207	1,187	1,160	1,137	1,090
Operating Revenue	1,455	1,405	1,351	1,301	1,316	1,247	1,207	1,187	1,160	1,137	1,090
Total Cost of Revenue	777	772	747	715	726	690	673	651	643	628	618
Operating Cost of Revenue	777	772	747	715	726	690	673	651	643	628	618
Total Operating Expenses	411	401	395	371	383	367	355	353	339	330	323
Selling, General & Admin Expense	332	323	317	298	313	297	287	280	275	267	261
Depreciation Expense	79	78	78	73	70	70	67	73	64	63	62
Total Other Income / (Expense), net	-28	-31	-25	-30	-29	-25	-34	-33	-32	-29	-41
Interest Expense	32	33	35	34	35	35	36	36	36	38	38
Interest & Investment Income	0.90	0.20	0.70	1.40	0.70	0.90	1.00	0.90	0.40	0.30	0.70
Other Income / (Expense), net	2.50	2.10	9.30	3.30	5.40	8.90	0.50	2.70	3.60	8.40	-3.60
Income Tax Expense	42	38	36	38	38	37	30	33	32	32	22
Net Income / (Loss) Discontinued Operations	-0.50	0.40	-0.70	-1.20	-1.30	-8.50	-1.30	-1.20	-1.00	-1.50	-19
Net Income / (Loss) Attributable to Noncontrolling Interest	45	43	39	32	26	32	28	26	26	-	-
Basic Earnings per Share	$1.50	$1.20	$1.08	$1.13	$1.12	$0.88	$0.85	$0.91	$0.88	$0.90	$0.45
Weighted Average Basic Shares Outstanding	100.50M	99.90M	99.90M	99.90M	99.80M	99.50M	99.50M	99.50M	99.40M	99.20M	99.20M
Diluted Earnings per Share	$1.48	$1.18	$1.06	$1.12	$1.10	$0.88	$0.84	$0.90	$0.87	$0.90	$0.45
Weighted Average Diluted Shares Outstanding	102.10M	102.20M	102.10M	102M	102.20M	101.30M	101.40M	101.10M	100.90M	100.40M	100.50M
Weighted Average Basic & Diluted Shares Outstanding	100.80M	100.71M	100.75M	100.63M	100.69M	100.14M	100.24M	100.23M	100.24M	99.73M	99.79M
Cash Dividends to Common per Share	$0.17	-	$0.17	$0.15	$0.15	$0.38	$0.15	$0.15	$0.15	$0.44	$0.15

This table details how cash moves in and out of Encompass Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	19	51	-67	-191	151	26	17	15	-6.10	-5.10
Net Cash From Operating Activities	1,003	851	706	716	705	635	762	658	640	502
Net Cash From Continuing Operating Activities	1,003	851	706	716	705	640	762	658	640	502
Net Income / (Loss) Continuing Operations	599	475	351	403	278	446	374	351	318	254
Consolidated Net Income / (Loss)	597	463	366	517	369	446	375	350	318	253
Net Income / (Loss) Discontinued Operations	-2.80	-12	15	114	91	-0.60	1.10	0.40	0.00	-0.90
Depreciation Expense	300	274	244	220	203	219	200	184	173	140
Amortization Expense	9.70	9.50	9.70	7.80	7.20	4.50	4.00	8.70	14	14
Non-Cash Adjustments To Reconcile Net Income	62	38	104	178	74	110	148	62	33	97
Changes in Operating Assets and Liabilities, net	33	54	-2.50	-93	143	-140	37	53	103	-2.80
Net Cash From Investing Activities	-653	-603	-627	-666	-408	-657	-425	-283	-230	-1,130
Net Cash From Continuing Investing Activities	-653	-603	-624	-547	-405	-657	-425	-283	-230	-1,130
Purchase of Property, Plant & Equipment	-643	-583	-584	-546	-401	-385	-271	-245	-203	-157
Purchase of Investments	-23	-23	-35	-9.00	-8.70	-33	-13	-8.50	-1.30	-7.10
Sale and/or Maturity of Investments	19	7.40	0.00	-	13	18	12	4.20	0.10	13
Other Investing Activities, net	-7.20	-4.10	-4.20	7.60	-3.80	-6.50	-2.70	8.80	-1.70	1.60
Net Cash From Discontinued Investing Activities	0.00	0.00	-3.50	-119	-3.00	-	-	-	0.10	0.50
Net Cash From Financing Activities	-331	-197	-146	-240	-146	48	-321	-360	-416	623
Net Cash From Continuing Financing Activities	-331	-197	-661	-230	-134	48	-321	-360	-416	623
Repayment of Debt	-335	-162	-755	-315	-1,126	-1,169	-429	-480	-529	-1,376
Repurchase of Common Equity	-31	0.00	0.00	-	-6.10	-46	0.00	-38	-66	-45
Payment of Dividends	-188	-175	-196	-213	-345	-351	-241	-143	-149	-132
Issuance of Debt	95	80	252	300	1,323	1,635	344	274	335	2,190
Issuance of Common Equity	140	68	64	57	35	16	13	21	3.50	3.00
Other Financing Activities, net	-12	-8.20	-27	-59	-15	-36	-8.30	6.80	-12	-17
Net Cash From Discontinued Financing Activities	0.00	0.00	515	-10	-12	-	-	-	-	-
Cash Interest Paid	147	148	178	168	168	156	150	151	164	121
Cash Income Taxes Paid	165	109	51	131	34	104	115	96	33	17

This table details how cash moves in and out of Encompass Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-0.30	-76	17	9.40	69	-37	-13	35	66	-51	-153
Net Cash From Operating Activities	289	279	268	217	239	201	215	207	228	172	70
Net Cash From Continuing Operating Activities	289	279	268	217	239	201	215	207	228	172	146
Net Income / (Loss) Continuing Operations	197	164	148	148	140	128	115	118	114	119	86
Consolidated Net Income / (Loss)	197	164	147	147	139	119	113	117	113	118	67
Net Income / (Loss) Discontinued Operations	-0.50	0.40	-0.70	-1.20	-1.30	-8.50	-1.30	-1.20	-1.00	-1.50	-19
Depreciation Expense	79	78	78	73	70	70	67	73	64	63	62
Non-Cash Adjustments To Reconcile Net Income	11	16	11	11	24	-4.40	19	16	7.80	-1.50	70
Changes in Operating Assets and Liabilities, net	1.30	11	30	-14	4.90	-1.80	14	-0.20	42	-18	-71
Net Cash From Investing Activities	-159	-204	-162	-158	-130	-208	-162	-129	-104	-206	-174
Net Cash From Continuing Investing Activities	-159	-204	-162	-158	-130	-208	-162	-129	-104	-207	-174
Purchase of Property, Plant & Equipment	-163	-199	-148	-157	-139	-212	-150	-122	-100	-209	-149
Sale and/or Maturity of Investments	11	1.00	0.90	1.00	16	0.40	6.00	0.80	0.20	-	-
Other Investing Activities, net	-6.40	-3.50	5.10	-2.50	-6.30	5.10	2.60	-7.40	-4.40	13	0.20
Net Cash From Financing Activities	-130	-151	-90	-50	-41	-30	-66	-44	-58	-17	-49
Net Cash From Continuing Financing Activities	-130	-151	-90	-50	-41	-30	-66	-44	-58	-16	4.70
Repayment of Debt	-88	-134	-140	-5.00	-56	-42	9.60	-80	-50	-34	-24
Repurchase of Common Equity	-32	-7.50	-6.80	-	-	-	-	-	-	-	-
Payment of Dividends	-51	-57	-48	-43	-41	-38	-48	-43	-47	-43	-50
Issuance of Debt	60	30	15	-	50	-	-	50	30	72	50
Issuance of Common Equity	0.00	0.70	106	15	18	14	8.40	29	17	9.00	20
Other Financing Activities, net	-20	16	-16	-	-12	36	-36	-	-7.70	-19	9.40

This table presents Encompass Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	6,535	6,102	5,637	6,865	6,446	6,081	5,175	2,089	4,682	4,606
Total Current Assets	887	842	717	921	949	756	662	117	655	599
Cash & Equivalents	85	69	22	49	224	95	69	54	41	62
Restricted Cash	38	35	32	63	65	57	-	62	61	46
Accounts Receivable	599	612	537	516	573	506	468	-	444	411
Prepaid Expenses	42	35	35	115	86	98	66	-	109	81
Other Current Assets	123	92	92	-	-	-	59	-	-	-
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	1,635	0.00	1,392	1,310
Total Noncurrent Assets	5,648	5,261	4,919	5,944	5,497	5,325	2,878	1,973	2,636	2,697
Goodwill	1,284	1,281	1,263	1,237	2,319	2,305	2,101	1,973	1,927	1,890
Intangible Assets	298	278	282	158	431	476	443	-	411	419
Other Noncurrent Operating Assets	4,066	3,701	3,374	3,005	2,747	2,541	291	-	221	197
Total Liabilities & Shareholders' Equity	6,535	6,102	5,637	6,865	6,446	6,081	5,175	0.00	4,682	4,606
Total Liabilities	3,686	3,805	3,775	4,466	4,444	4,148	3,356	0.00	3,615	3,706
Total Current Liabilities	841	656	576	749	717	721	673	0.00	476	426
Short-Term Debt	139	25	25	38	38	39	36	-	37	37
Accounts Payable	171	170	133	134	115	95	90	-	68	62
Current Employee Benefit Liabilities	228	208	168	199	254	211	188	-	147	126
Other Current Liabilities	265	212	207	201	263	344	334	-	197	172
Other Current Nonoperating Liabilities	39	43	43	177	47	32	24	-	26	30
Total Noncurrent Liabilities	2,845	3,149	3,199	3,717	3,727	3,427	2,684	0.00	3,139	3,279
Long-Term Debt	2,359	2,688	2,742	3,241	3,251	3,023	2,479	-	2,979	3,135
Asset Retirement Reserve & Litigation Obligation	139	132	129	124	121	117	120	-	110	102
Noncurrent Deferred & Payable Income Tax Liabilities	105	87	83	23	52	0.00	-	-	-	-
Other Noncurrent Operating Liabilities	242	242	245	229	303	287	86	-	50	43
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Redeemable Noncontrolling Interest	57	42	36	42	32	240	262	-	138	121
Total Equity & Noncontrolling Interests	2,793	2,255	1,826	2,357	1,970	1,693	1,557	0.00	929	779
Total Preferred & Common Equity	2,067	1,648	1,310	1,911	1,588	1,352	1,277	0.00	736	611
Total Common Equity	2,067	1,648	1,310	1,911	1,588	1,352	1,277	0.00	736	611
Common Stock	1,848	1,788	1,731	2,291	2,328	2,371	2,590	-	2,800	2,836
Retained Earnings	797	407	116	142	-242	-527	-885	-	-1,448	-1,696
Treasury Stock	-578	-547	-537	-521	-497	-492	-428	-	-615	-527
Noncontrolling Interest	726	608	516	446	382	341	280	-	193	168

This table presents Encompass Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	6,641	6,458	6,389	6,231	5,964	5,861	5,747	5,476
Total Current Assets	911	934	938	930	814	824	762	734
Cash & Equivalents	96	148	154	134	100	118	85	60
Restricted Cash	27	51	28	38	42	37	34	44
Accounts Receivable	623	576	590	619	536	532	515	500
Other Current Assets	165	159	166	138	137	138	128	130
Plant, Property, & Equipment, net	3,724	3,524	3,439	3,370	3,186	0.00	2,988	2,807
Total Noncurrent Assets	2,007	2,001	2,012	1,931	1,964	5,037	1,997	1,935
Goodwill	1,284	1,284	1,284	1,281	1,281	1,271	1,271	1,247
Intangible Assets	295	296	303	272	276	278	287	285
Other Noncurrent Operating Assets	428	421	425	378	407	3,488	439	402
Total Liabilities & Shareholders' Equity	6,641	6,458	6,389	6,231	5,964	5,861	5,747	5,476
Total Liabilities	3,704	3,733	3,859	3,828	3,775	3,804	3,784	3,728
Total Current Liabilities	856	897	695	680	639	655	592	605
Short-Term Debt	139	233	33	26	24	23	26	26
Accounts Payable	159	170	164	166	165	156	141	134
Other Current Liabilities	558	494	498	489	450	442	393	444
Total Noncurrent Liabilities	2,848	2,835	3,164	3,148	3,136	3,149	3,192	3,123
Long-Term Debt	2,333	2,345	2,684	2,683	2,693	2,698	2,723	2,719
Noncurrent Deferred & Payable Income Tax Liabilities	114	97	91	94	80	83	87	47
Other Noncurrent Operating Liabilities	401	394	389	372	363	368	383	357
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	56	57	49	41	42	39	38	38
Total Equity & Noncontrolling Interests	2,882	2,669	2,481	2,362	2,148	2,018	1,926	1,710
Total Preferred & Common Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Noncontrolling Interest	2,882	2,669	2,481	2,362	2,148	2,018	1,926	1,710

This table displays calculated financial ratios and metrics derived from Encompass Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	11.91%	10.41%	8.31%	12.58%	-22.56%	7.66%	9.28%	15.17%	31.46%
EBITDA Growth	15.81%	17.37%	-1.79%	19.85%	-21.14%	13.25%	-1.24%	18.68%	14.09%
EBIT Growth	18.34%	19.60%	-6.28%	24.42%	-25.86%	14.43%	-3.32%	18.02%	10.75%
NOPAT Growth	20.75%	16.77%	-6.85%	26.55%	-24.35%	15.06%	4.18%	22.13%	5.08%
Net Income Growth	28.86%	26.54%	-29.25%	40.24%	-17.27%	52.51%	7.82%	35.23%	-17.52%
EPS Growth	28.53%	28.52%	-34.31%	40.24%	-17.27%	23.21%	3.17%	35.60%	-16.59%
Operating Cash Flow Growth	17.87%	20.54%	-1.40%	1.58%	10.92%	-16.67%	15.81%	27.53%	12.83%
Free Cash Flow Firm Growth	55.41%	3,648.60%	-100.47%	497.54%	749.69%	97.96%	-173.70%	150.18%	-70.65%
Invested Capital Growth	6.35%	7.14%	12.06%	-18.36%	3.54%	13.69%	117.39%	0.34%	41.76%
Revenue Q/Q Growth	3.03%	2.33%	17.62%	9.54%	-22.71%	1.96%	2.08%	0.17%	9.18%
EBITDA Q/Q Growth	4.66%	2.69%	18.56%	3.65%	-13.60%	7.52%	-5.61%	2.90%	11.06%
EBIT Q/Q Growth	4.19%	1.45%	24.06%	-1.58%	-14.19%	8.43%	-8.67%	1.15%	8.25%
NOPAT Q/Q Growth	6.45%	0.92%	20.70%	0.21%	-14.19%	10.99%	-10.48%	3.98%	3.04%
Net Income Q/Q Growth	8.18%	-4.14%	6.83%	18.76%	-24.66%	39.66%	-9.22%	6.68%	-8.27%
EPS Q/Q Growth	5.44%	-2.53%	-1.82%	18.76%	-24.66%	-12.38%	-14.33%	7.92%	3.24%
Operating Cash Flow Q/Q Growth	8.41%	3.50%	7.36%	-17.88%	10.01%	6.22%	3.67%	1.11%	14.51%
Free Cash Flow Firm Q/Q Growth	21.69%	26.37%	-100.51%	651.35%	-60.62%	88.73%	-585.24%	166.98%	-61.66%
Invested Capital Q/Q Growth	3.10%	3.85%	5.22%	-22.69%	0.99%	-4.99%	-0.37%	1.27%	36.46%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	44.94%	44.67%	43.71%	45.55%	44.90%	42.34%	44.97%	45.48%	45.68%
EBITDA Margin	22.22%	21.47%	20.20%	22.27%	20.92%	20.55%	19.53%	23.01%	22.33%
Operating Margin	16.09%	15.24%	14.49%	16.42%	14.79%	15.04%	14.72%	17.81%	17.28%
EBIT Margin	16.46%	15.57%	14.37%	16.61%	15.03%	15.70%	14.77%	17.89%	17.46%
Profit (Net Income) Margin	11.10%	9.64%	8.41%	12.88%	10.34%	9.68%	6.83%	6.80%	5.79%
Tax Burden Percent	79.59%	76.25%	81.17%	102.42%	104.51%	79.28%	59.27%	51.37%	46.28%
Interest Burden Percent	84.74%	81.23%	72.13%	75.72%	65.84%	77.77%	78.06%	73.96%	71.64%
Effective Tax Rate	20.04%	21.77%	22.21%	20.18%	21.17%	20.61%	24.11%	34.00%	35.87%
Return on Invested Capital (ROIC)	13.54%	11.97%	11.22%	11.48%	8.38%	12.00%	15.26%	10.70%	10.29%
ROIC Less NNEP Spread (ROIC-NNEP)	9.80%	7.92%	5.67%	11.10%	6.81%	8.16%	6.91%	4.72%	3.74%
Return on Net Nonoperating Assets (RNNOA)	9.64%	10.30%	5.95%	12.02%	10.37%	11.77%	16.88%	14.47%	11.27%
Return on Equity (ROE)	23.19%	22.26%	17.17%	23.50%	18.75%	23.77%	32.14%	25.17%	21.57%
Cash Return on Invested Capital (CROIC)	7.38%	5.07%	-0.16%	31.70%	4.90%	-0.82%	-58.71%	10.36%	-24.25%
Operating Return on Assets (OROA)	14.00%	12.74%	10.00%	10.02%	8.56%	12.85%	17.39%	14.03%	13.81%
Return on Assets (ROA)	9.44%	7.89%	5.85%	7.77%	5.89%	7.92%	8.05%	5.33%	4.58%
Return on Common Equity (ROCE)	16.73%	15.83%	12.98%	18.69%	14.01%	16.66%	22.56%	17.24%	13.78%
Return on Equity Simple (ROE_SIMPLE)	28.86%	28.10%	27.92%	27.06%	23.22%	32.97%	22.90%	33.65%	29.95%
Net Operating Profit after Tax (NOPAT)	691	572	490	526	416	550	478	428	351
NOPAT Margin	12.87%	11.92%	11.27%	13.11%	11.66%	11.94%	11.17%	11.75%	11.08%
Net Nonoperating Expense Percent (NNEP)	3.74%	4.05%	5.55%	0.38%	1.57%	3.84%	8.35%	5.99%	6.55%
Return On Investment Capital (ROIC_SIMPLE)	13.07%	11.52%	10.67%	-	-	-	-	-	-
Cost of Revenue to Revenue	55.06%	55.33%	56.29%	54.45%	55.10%	57.66%	55.03%	54.52%	54.32%
SG&A Expenses to Revenue	23.28%	23.73%	23.61%	23.65%	24.33%	22.55%	22.54%	20.97%	22.04%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	28.85%	29.43%	29.21%	29.12%	30.10%	27.30%	30.25%	27.67%	28.40%
Earnings before Interest and Taxes (EBIT)	885	748	625	667	536	723	632	652	552
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,194	1,031	878	894	746	946	836	838	706
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.49	4.03	4.48	3.30	4.96	4.75	4.42	4.48	4.53
Price to Tangible Book Value (P/TBV)	19.14	75.45	0.00	12.23	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.73	1.38	1.35	1.57	2.21	1.40	1.32	0.91	0.88
Price to Earnings (P/E)	20.38	18.86	21.66	15.31	27.70	17.92	15.04	13.33	15.26
Dividend Yield	0.67%	0.91%	1.37%	1.77%	1.41%	1.69%	1.82%	2.56%	2.91%
Earnings Yield	4.91%	5.30%	4.62%	6.53%	3.61%	5.58%	6.65%	7.50%	6.55%
Enterprise Value to Invested Capital (EV/IC)	2.36	2.00	1.98	2.42	2.24	2.03	2.01	1.63	1.53
Enterprise Value to Revenue (EV/Rev)	2.32	2.06	2.10	2.48	3.16	2.15	2.02	1.80	1.94
Enterprise Value to EBITDA (EV/EBITDA)	10.42	9.60	10.40	11.14	15.12	10.48	10.33	7.81	8.67
Enterprise Value to EBIT (EV/EBIT)	14.07	13.24	14.61	14.94	21.05	13.72	13.66	10.05	11.09
Enterprise Value to NOPAT (EV/NOPAT)	18.00	17.29	18.63	18.93	27.13	18.04	18.07	15.29	17.46
Enterprise Value to Operating Cash Flow (EV/OCF)	12.41	11.63	12.94	13.92	16.01	15.61	11.32	10.23	12.20
Enterprise Value to Free Cash Flow (EV/FCFF)	33.01	40.80	0.00	6.86	46.40	0.00	0.00	15.79	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.88	1.18	1.49	1.37	1.64	1.58	1.38	2.83	3.52
Long-Term Debt to Equity	0.83	1.17	1.47	1.35	1.62	1.56	1.36	2.79	3.48
Financial Leverage	0.98	1.30	1.05	1.08	1.52	1.44	2.44	3.07	3.01
Leverage Ratio	2.46	2.82	2.93	3.02	3.18	3.00	3.99	4.72	4.71
Compound Leverage Factor	2.08	2.29	2.12	2.29	2.10	2.33	3.12	3.49	3.37
Debt to Total Capital	46.71%	54.15%	59.78%	57.74%	62.17%	61.31%	58.03%	73.87%	77.89%
Short-Term Debt to Total Capital	2.59%	0.50%	0.54%	0.67%	0.72%	0.79%	0.83%	0.91%	0.90%
Long-Term Debt to Total Capital	44.12%	53.65%	59.23%	57.08%	61.44%	60.52%	57.20%	72.96%	76.98%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	14.63%	12.97%	11.92%	8.59%	7.82%	11.62%	12.51%	8.11%	7.10%
Common Equity to Total Capital	38.66%	32.89%	28.31%	33.66%	30.02%	27.07%	29.46%	18.02%	15.02%
Debt to EBITDA	2.09	2.63	3.15	3.67	4.41	3.24	3.01	3.60	4.49
Net Debt to EBITDA	1.99	2.53	3.09	3.54	4.02	3.08	2.93	3.48	4.34
Long-Term Debt to EBITDA	1.98	2.61	3.12	3.62	4.36	3.20	2.97	3.55	4.44
Debt to NOPAT	3.61	4.74	5.64	6.23	7.91	5.57	5.26	7.04	9.05
Net Debt to NOPAT	3.44	4.56	5.54	6.02	7.21	5.29	5.12	6.81	8.74
Long-Term Debt to NOPAT	3.41	4.70	5.59	6.16	7.82	5.50	5.19	6.96	8.94
Altman Z-Score	2.96	2.37	2.13	1.81	1.88	1.97	2.00	1.40	1.06
Noncontrolling Interest Sharing Ratio	27.82%	28.88%	24.40%	20.48%	25.27%	29.92%	29.80%	31.52%	36.12%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	1.05	1.28	1.25	1.23	1.32	1.05	0.98	1.38	1.40
Quick Ratio	0.81	1.04	0.97	0.75	1.11	0.83	0.80	1.02	1.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	377	243	-6.84	1,453	243	-37	-1,838	414	-826
Operating Cash Flow to CapEx	156.08%	145.91%	120.84%	131.17%	175.69%	164.84%	281.85%	357.65%	329.18%
Free Cash Flow to Firm to Interest Expense	2.73	1.69	-0.04	8.79	1.31	-0.22	-12.48	2.31	-5.00
Operating Cash Flow to Interest Expense	7.27	5.93	3.99	4.33	3.79	3.80	5.18	3.57	3.04
Operating Cash Flow Less CapEx to Interest Expense	2.61	1.87	0.69	1.03	1.63	1.49	3.34	2.57	2.11
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.85	0.82	0.70	0.60	0.57	0.82	1.18	0.78	0.79
Accounts Receivable Turnover	8.88	8.36	8.26	7.38	6.61	9.46	0.00	8.53	8.62
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.70	2.72
Accounts Payable Turnover	17.35	17.54	18.34	17.56	18.75	28.77	0.00	30.58	29.88
Days Sales Outstanding (DSO)	41.11	43.65	44.18	49.48	55.21	38.59	0.00	42.80	42.33
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	21.04	20.81	19.90	20.79	19.46	12.69	0.00	11.94	12.22
Cash Conversion Cycle (CCC)	20.07	22.84	24.28	28.70	35.75	25.90	0.00	30.86	30.12
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	5,263	4,948	4,618	4,121	5,048	4,876	4,288	4,008	3,994
Invested Capital Turnover	1.05	1.00	1.00	0.88	0.72	1.01	1.37	0.91	0.93
Increase / (Decrease) in Invested Capital	314	330	497	-927	173	587	2,316	14	1,177
Enterprise Value (EV)	12,444	9,898	9,134	9,963	11,284	9,919	8,632	6,546	6,123
Market Capitalization	9,287	6,640	5,869	6,309	7,871	6,429	5,645	3,300	2,770
Book Value per Share	$20.52	$16.44	$13.13	$19.21	$15.97	$13.71	$12.91	$8.20	$6.69
Tangible Book Value per Share	$4.82	$0.88	($2.36)	$5.19	($11.69)	($14.50)	($12.81)	($17.85)	($18.57)
Total Capital	5,347	5,010	4,629	5,678	5,291	4,995	4,333	4,083	4,072
Total Debt	2,498	2,713	2,767	3,278	3,289	3,063	2,514	3,016	3,172
Total Long-Term Debt	2,359	2,688	2,742	3,241	3,251	3,023	2,479	2,979	3,135
Net Debt	2,375	2,608	2,714	3,166	3,000	2,910	2,445	2,915	3,064
Capital Expenditures (CapEx)	643	583	584	546	401	385	271	179	153
Debt-free, Cash-free Net Working Capital (DFCFNWC)	61	106	113	99	-20	-78	-44	115	102
Debt-free Net Working Capital (DFNWC)	185	210	167	210	270	74	25	216	209
Net Working Capital (NWC)	46	185	141	173	231	35	-10	179	172
Net Nonoperating Expense (NNE)	95	109	124	9.14	47	104	186	181	168
Net Nonoperating Obligations (NNO)	2,413	2,651	2,756	1,722	3,047	2,943	2,470	2,941	3,094
Total Depreciation and Amortization (D&A)	309	283	253	227	210	223	204	186	154
Debt-free, Cash-free Net Working Capital to Revenue	1.14%	2.21%	2.60%	2.45%	-0.56%	-1.70%	-1.02%	3.15%	3.21%
Debt-free Net Working Capital to Revenue	3.43%	4.38%	3.83%	5.24%	7.56%	1.61%	0.59%	5.93%	6.61%
Net Working Capital to Revenue	0.85%	3.86%	3.25%	4.30%	6.49%	0.76%	-0.24%	4.91%	5.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$4.53	$3.51	$2.72	$3.30	$2.28	$2.91	$2.37	$2.21	$1.61
Adjusted Weighted Average Basic Shares Outstanding	99.90M	99.50M	99.20M	124.35M	123.84M	123.09M	122.96M	111.91M	112.29M
Adjusted Diluted Earnings per Share	$4.46	$3.47	$2.70	$3.27	$2.27	$2.87	$2.33	$2.06	$1.52
Adjusted Weighted Average Diluted Shares Outstanding	102.20M	101.30M	100.40M	125.85M	125.35M	124.85M	125.35M	124.97M	126.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	100.71M	100.14M	99.73M	124.90M	124.68M	123.63M	124.02M	111.85M	112.76M
Normalized Net Operating Profit after Tax (NOPAT)	691	572	490	526	418	550	517	428	355
Normalized NOPAT Margin	12.87%	11.92%	11.27%	13.11%	11.72%	11.94%	12.09%	11.75%	11.24%
Pre Tax Income Margin	13.95%	12.65%	10.37%	12.58%	9.90%	12.21%	11.53%	13.23%	12.51%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	6.41	5.21	3.53	4.03	2.88	4.32	4.29	3.63	3.34
NOPAT to Interest Expense	5.01	3.99	2.77	3.18	2.24	3.28	3.24	2.39	2.12
EBIT Less CapEx to Interest Expense	1.75	1.15	0.23	0.73	0.73	2.02	2.45	2.63	2.42
NOPAT Less CapEx to Interest Expense	0.35	-0.07	-0.53	-0.12	0.08	0.98	1.41	1.39	1.20
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	31.48%	37.82%	53.46%	41.24%	93.55%	78.82%	82.55%	60.06%	71.87%
Augmented Payout Ratio	36.69%	37.82%	53.46%	41.24%	95.20%	89.12%	82.55%	86.55%	96.61%

This table displays calculated financial ratios and metrics derived from Encompass Health's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.59%	12.69%	11.94%	9.61%	13.41%	9.63%	10.78%	11.73%	9.54%	134.01%	7.79%
EBITDA Growth	23.13%	16.18%	20.06%	12.58%	15.08%	6.96%	19.48%	27.31%	19.06%	103.40%	1.27%
EBIT Growth	26.59%	17.91%	21.40%	17.31%	16.85%	5.69%	24.24%	30.40%	22.28%	181.17%	-13.45%
NOPAT Growth	35.28%	28.49%	18.49%	18.89%	16.70%	3.76%	20.01%	33.05%	16.49%	129.16%	-10.91%
Net Income Growth	41.57%	37.87%	29.72%	25.00%	22.51%	-14.38%	149.78%	64.38%	2.91%	20.22%	-64.17%
EPS Growth	34.55%	34.09%	26.19%	24.44%	26.44%	-2.22%	86.67%	83.67%	0.00%	-3.23%	-55.00%
Operating Cash Flow Growth	20.85%	38.71%	24.44%	5.18%	4.78%	16.72%	206.99%	-15.49%	4.11%	39.10%	-60.53%
Free Cash Flow Firm Growth	30.62%	31.44%	26.54%	-124.75%	-115.99%	48.54%	-122.03%	599.21%	390.68%	-135.94%	632.32%
Invested Capital Growth	7.04%	6.35%	7.13%	9.54%	7.55%	7.14%	8.55%	-16.99%	-18.00%	12.06%	-17.66%
Revenue Q/Q Growth	3.59%	4.00%	3.83%	-1.12%	5.55%	3.31%	1.67%	2.30%	2.03%	4.39%	2.54%
EBITDA Q/Q Growth	11.62%	5.26%	1.71%	3.04%	5.32%	8.78%	-4.63%	5.32%	-2.11%	21.51%	1.62%
EBIT Q/Q Growth	14.97%	7.33%	-0.23%	2.82%	7.09%	10.51%	-3.59%	2.41%	-3.14%	29.90%	1.19%
NOPAT Q/Q Growth	16.68%	12.36%	-1.79%	5.06%	10.83%	3.61%	-1.45%	3.13%	-1.47%	19.84%	9.25%
Net Income Q/Q Growth	19.67%	11.62%	0.41%	5.55%	-5.71%	5.03%	-3.24%	3.44%	-18.55%	206.39%	-36.33%
EPS Q/Q Growth	25.42%	11.32%	-5.36%	1.82%	25.00%	4.76%	-6.67%	3.45%	-3.33%	100.00%	-8.16%
Operating Cash Flow Q/Q Growth	3.52%	4.11%	23.18%	-8.96%	18.81%	-6.60%	4.11%	-9.30%	32.35%	145.65%	-71.34%
Free Cash Flow Firm Q/Q Growth	-1.58%	26.88%	36.47%	-47.04%	-30.86%	21.65%	-121.40%	-4.98%	422.95%	-133.54%	585.04%
Invested Capital Q/Q Growth	0.46%	3.10%	0.78%	2.54%	0.68%	3.85%	3.05%	0.68%	-0.56%	5.22%	-21.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	46.60%	45.09%	44.74%	45.07%	44.86%	44.63%	44.25%	45.20%	44.61%	44.83%	43.28%
EBITDA Margin	23.96%	22.23%	21.97%	22.43%	21.52%	21.57%	20.48%	21.83%	21.21%	22.11%	18.99%
Operating Margin	18.35%	16.53%	15.48%	16.57%	15.77%	15.23%	14.86%	15.49%	15.39%	15.80%	13.62%
EBIT Margin	18.52%	16.68%	16.17%	16.82%	16.18%	15.94%	14.91%	15.72%	15.70%	16.54%	13.29%
Profit (Net Income) Margin	13.50%	11.69%	10.89%	11.26%	10.55%	9.55%	9.40%	9.87%	9.76%	12.23%	4.17%
Tax Burden Percent	82.36%	81.53%	80.03%	78.76%	77.80%	72.27%	78.21%	77.51%	77.50%	92.18%	42.31%
Interest Burden Percent	88.53%	85.92%	84.16%	84.97%	83.80%	82.90%	80.60%	81.03%	80.24%	80.22%	74.10%
Effective Tax Rate	17.44%	18.67%	19.59%	20.59%	21.47%	22.57%	20.90%	21.69%	21.82%	21.14%	20.32%
Return on Invested Capital (ROIC)	16.33%	14.15%	13.15%	13.77%	12.88%	11.84%	12.05%	10.89%	10.51%	12.40%	8.26%
ROIC Less NNEP Spread (ROIC-NNEP)	15.35%	13.18%	12.30%	12.81%	11.94%	10.80%	10.96%	9.93%	9.59%	12.28%	5.69%
Return on Net Nonoperating Assets (RNNOA)	14.04%	12.97%	12.40%	14.24%	14.13%	14.05%	14.52%	12.07%	12.35%	12.91%	8.00%
Return on Equity (ROE)	30.37%	27.12%	25.56%	28.01%	27.01%	25.88%	26.58%	22.95%	22.86%	25.31%	16.25%
Cash Return on Invested Capital (CROIC)	7.84%	7.38%	6.28%	3.76%	5.23%	5.07%	4.19%	29.24%	29.79%	-0.16%	27.73%
Operating Return on Assets (OROA)	15.86%	14.19%	13.57%	13.93%	13.39%	13.04%	12.23%	11.11%	11.01%	11.51%	8.06%
Return on Assets (ROA)	11.56%	9.94%	9.14%	9.32%	8.73%	7.81%	7.71%	6.98%	6.85%	8.51%	2.53%
Return on Common Equity (ROCE)	0.00%	19.57%	0.00%	0.00%	0.00%	18.41%	0.00%	0.00%	0.00%	19.14%	0.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	220	189	168	171	163	147	142	144	140	142	118
NOPAT Margin	15.15%	13.45%	12.45%	13.16%	12.38%	11.79%	11.76%	12.13%	12.03%	12.46%	10.85%
Net Nonoperating Expense Percent (NNEP)	0.98%	0.98%	0.85%	0.97%	0.94%	1.03%	1.09%	0.96%	0.92%	0.12%	2.57%
Return On Investment Capital (ROIC_SIMPLE)	4.12%	3.57%	-	-	-	2.96%	-	-	-	3.09%	-
Cost of Revenue to Revenue	53.40%	54.91%	55.26%	54.93%	55.14%	55.37%	55.75%	54.80%	55.39%	55.17%	56.72%
SG&A Expenses to Revenue	22.81%	23.00%	23.46%	22.90%	23.75%	23.78%	23.81%	23.60%	23.71%	23.46%	23.96%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	28.25%	28.56%	29.27%	28.50%	29.10%	29.40%	29.39%	29.71%	29.21%	29.02%	29.66%
Earnings before Interest and Taxes (EBIT)	270	234	218	219	213	199	180	187	182	188	145
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	349	312	297	292	283	269	247	259	246	251	207
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	4.49	0.00	0.00	0.00	4.03	0.00	0.00	0.00	4.48	0.00
Price to Tangible Book Value (P/TBV)	0.00	19.14	0.00	0.00	0.00	75.45	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.85	1.73	1.86	1.70	1.67	1.38	1.42	1.47	1.20	1.35	1.20
Price to Earnings (P/E)	20.58	20.38	22.98	21.58	21.91	18.86	18.88	21.45	19.69	21.66	16.26
Dividend Yield	0.63%	0.67%	0.62%	0.70%	0.73%	0.91%	0.90%	1.31%	1.36%	1.37%	1.97%
Earnings Yield	4.86%	4.91%	4.35%	4.63%	4.56%	5.30%	5.30%	4.66%	5.08%	4.62%	6.15%
Enterprise Value to Invested Capital (EV/IC)	2.93	2.36	2.90	2.70	2.67	2.00	2.40	2.46	2.16	1.98	2.01
Enterprise Value to Revenue (EV/Rev)	2.81	2.32	2.84	2.70	2.66	2.06	2.44	2.48	2.23	2.10	2.39
Enterprise Value to EBITDA (EV/EBITDA)	12.38	10.42	12.98	12.54	12.46	9.60	11.40	11.78	10.94	10.40	11.92
Enterprise Value to EBIT (EV/EBIT)	16.44	14.07	17.45	16.89	16.95	13.24	15.53	16.18	15.09	14.61	17.53
Enterprise Value to NOPAT (EV/NOPAT)	20.66	18.00	22.81	21.97	22.14	17.29	20.18	20.90	19.47	18.63	21.74
Enterprise Value to Operating Cash Flow (EV/OCF)	14.70	12.41	16.01	15.69	15.31	11.63	13.92	16.78	13.89	12.94	13.43
Enterprise Value to Free Cash Flow (EV/FCFF)	38.57	33.01	47.81	75.23	52.92	40.80	59.62	7.62	6.54	0.00	6.55
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.84	0.88	0.95	1.07	1.13	1.18	1.24	1.32	1.40	1.49	1.57
Long-Term Debt to Equity	0.79	0.83	0.86	1.06	1.12	1.17	1.23	1.31	1.39	1.47	1.56
Financial Leverage	0.91	0.98	1.01	1.11	1.18	1.30	1.33	1.22	1.29	1.05	1.41
Leverage Ratio	2.41	2.46	2.53	2.67	2.74	2.82	2.91	2.81	2.85	2.93	3.02
Compound Leverage Factor	2.13	2.11	2.13	2.27	2.30	2.34	2.34	2.28	2.29	2.35	2.24
Debt to Total Capital	45.70%	46.71%	48.60%	51.78%	52.98%	54.15%	55.38%	56.94%	58.33%	59.78%	61.10%
Short-Term Debt to Total Capital	2.56%	2.59%	4.39%	0.62%	0.50%	0.50%	0.49%	0.48%	0.55%	0.54%	0.58%
Long-Term Debt to Total Capital	43.13%	44.12%	44.21%	51.16%	52.48%	53.65%	54.89%	56.47%	57.78%	59.23%	60.52%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	54.30%	14.63%	51.40%	48.22%	47.02%	12.97%	44.62%	43.06%	41.67%	11.92%	38.90%
Common Equity to Total Capital	0.00%	38.66%	0.00%	0.00%	0.00%	32.89%	0.00%	0.00%	0.00%	28.31%	0.00%
Debt to EBITDA	1.98	2.09	2.26	2.49	2.56	2.63	2.71	2.82	3.03	3.15	3.71
Net Debt to EBITDA	1.88	1.99	2.09	2.32	2.40	2.53	2.57	2.66	2.90	3.09	3.57
Long-Term Debt to EBITDA	1.87	1.98	2.06	2.46	2.53	2.61	2.68	2.80	3.00	3.12	3.67
Debt to NOPAT	3.30	3.61	3.97	4.36	4.55	4.74	4.79	5.01	5.39	5.64	6.76
Net Debt to NOPAT	3.14	3.44	3.66	4.07	4.26	4.56	4.54	4.72	5.15	5.54	6.50
Long-Term Debt to NOPAT	3.12	3.41	3.61	4.31	4.50	4.70	4.75	4.96	5.34	5.59	6.69
Altman Z-Score	2.62	2.63	2.49	2.29	2.25	2.07	1.98	1.98	1.76	1.87	1.51
Noncontrolling Interest Sharing Ratio	100.00%	27.82%	100.00%	100.00%	100.00%	28.88%	100.00%	100.00%	100.00%	24.40%	100.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.06	1.05	1.04	1.35	1.37	1.28	1.27	1.26	1.29	1.25	1.21
Quick Ratio	0.84	0.81	0.81	1.07	1.11	1.04	0.99	0.99	1.01	0.97	0.93
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-127	-125	-171	-270	-184	-183	-233	1,091	1,148	-355	1,060
Operating Cash Flow to CapEx	176.95%	140.31%	181.56%	138.56%	171.31%	94.95%	143.75%	169.57%	228.36%	82.31%	46.95%
Free Cash Flow to Firm to Interest Expense	-4.00	-3.78	-4.86	-7.87	-5.21	-5.24	-6.50	30.04	31.53	-9.48	27.74
Operating Cash Flow to Interest Expense	9.08	8.40	7.59	6.34	6.78	5.76	5.99	5.69	6.26	4.59	1.84
Operating Cash Flow Less CapEx to Interest Expense	3.95	2.41	3.41	1.76	2.82	-0.31	1.82	2.34	3.52	-0.99	-2.07
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.86	0.85	0.84	0.83	0.83	0.82	0.82	0.71	0.70	0.70	0.61
Accounts Receivable Turnover	8.87	8.88	9.38	9.04	8.74	8.36	9.06	7.68	7.43	8.26	6.50
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.55	0.00	1.55	0.00	1.56	0.00	1.57	0.00	1.57	0.00	0.00
Accounts Payable Turnover	18.51	17.35	17.14	17.52	17.83	17.54	17.32	17.26	17.25	18.34	14.25
Days Sales Outstanding (DSO)	41.14	41.11	38.93	40.38	41.74	43.65	40.30	47.52	49.13	44.18	56.17
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	19.72	21.04	21.29	20.83	20.47	20.81	21.07	21.14	21.15	19.90	25.62
Cash Conversion Cycle (CCC)	21.42	20.07	17.63	19.55	21.28	22.84	19.22	26.38	27.98	24.28	30.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,287	5,263	5,104	5,065	4,939	4,948	4,765	4,623	4,592	4,618	4,389
Invested Capital Turnover	1.08	1.05	1.06	1.05	1.04	1.00	1.03	0.90	0.87	1.00	0.76
Increase / (Decrease) in Invested Capital	348	314	340	441	347	330	375	-947	-1,008	497	-941
Enterprise Value (EV)	15,469	12,444	14,812	13,687	13,194	9,898	11,445	11,355	9,932	9,134	8,831
Market Capitalization	10,183	9,287	9,707	8,623	8,255	6,640	6,680	6,732	5,340	5,869	4,443
Book Value per Share	$0.00	$20.52	$0.00	$0.00	$0.00	$16.44	$0.00	$0.00	$0.00	$13.13	$0.00
Tangible Book Value per Share	($15.67)	$4.82	($15.70)	($15.76)	($15.51)	$0.88	($15.54)	($15.45)	($15.62)	($2.36)	($15.36)
Total Capital	5,410	5,347	5,303	5,247	5,112	5,010	4,906	4,777	4,712	4,629	4,493
Total Debt	2,472	2,498	2,578	2,717	2,708	2,713	2,717	2,720	2,749	2,767	2,745
Total Long-Term Debt	2,333	2,359	2,345	2,684	2,683	2,688	2,693	2,698	2,723	2,742	2,719
Net Debt	2,349	2,375	2,379	2,535	2,536	2,608	2,575	2,566	2,629	2,714	2,641
Capital Expenditures (CapEx)	163	199	148	157	139	212	150	122	100	209	149
Debt-free, Cash-free Net Working Capital (DFCFNWC)	71	61	71	94	102	106	57	38	76	113	51
Debt-free Net Working Capital (DFNWC)	194	185	270	276	275	210	198	192	196	167	155
Net Working Capital (NWC)	55	46	37	244	250	185	175	169	170	141	129
Net Nonoperating Expense (NNE)	24	25	21	25	24	28	29	27	26	2.61	73
Net Nonoperating Obligations (NNO)	2,349	2,413	2,379	2,535	2,536	2,651	2,575	2,566	2,629	2,756	2,642
Total Depreciation and Amortization (D&A)	79	78	78	73	70	70	67	73	64	63	62
Debt-free, Cash-free Net Working Capital to Revenue	1.28%	1.14%	1.35%	1.85%	2.07%	2.21%	1.22%	0.83%	1.71%	2.60%	1.38%
Debt-free Net Working Capital to Revenue	3.51%	3.43%	5.17%	5.44%	5.55%	4.38%	4.23%	4.19%	4.40%	3.83%	4.20%
Net Working Capital to Revenue	1.00%	0.85%	0.70%	4.80%	5.03%	3.86%	3.72%	3.69%	3.81%	3.25%	3.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.50	$1.20	$1.08	$1.13	$1.12	$0.88	$0.85	$0.91	$0.88	$0.90	$0.45
Adjusted Weighted Average Basic Shares Outstanding	100.50M	99.90M	99.90M	99.90M	99.80M	99.50M	99.50M	99.50M	99.40M	99.20M	99.20M
Adjusted Diluted Earnings per Share	$1.48	$1.18	$1.06	$1.12	$1.10	$0.88	$0.84	$0.90	$0.87	$0.90	$0.45
Adjusted Weighted Average Diluted Shares Outstanding	102.10M	102.20M	102.10M	102M	102.20M	101.30M	101.40M	101.10M	100.90M	100.40M	100.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.88	$0.00	$0.00	$0.00	$0.90	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	100.80M	100.71M	100.75M	100.63M	100.69M	100.14M	100.24M	100.23M	100.24M	99.73M	99.79M
Normalized Net Operating Profit after Tax (NOPAT)	220	189	168	171	163	147	142	144	140	142	118
Normalized NOPAT Margin	15.15%	13.45%	12.45%	13.16%	12.38%	11.79%	11.76%	12.13%	12.03%	12.46%	10.85%
Pre Tax Income Margin	16.39%	14.33%	13.60%	14.29%	13.56%	13.22%	12.01%	12.74%	12.60%	13.27%	9.85%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	8.47	7.06	6.19	6.38	6.05	5.70	5.01	5.14	5.01	5.02	3.79
NOPAT to Interest Expense	6.93	5.69	4.76	4.99	4.63	4.21	3.95	3.97	3.84	3.78	3.10
EBIT Less CapEx to Interest Expense	3.35	1.08	2.01	1.81	2.09	-0.37	0.84	1.78	2.26	-0.56	-0.12
NOPAT Less CapEx to Interest Expense	1.80	-0.29	0.58	0.42	0.67	-1.85	-0.22	0.61	1.09	-1.80	-0.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	30.28%	31.48%	30.64%	32.54%	34.45%	37.82%	37.41%	44.17%	52.48%	53.46%	59.82%
Augmented Payout Ratio	39.94%	36.69%	30.64%	32.54%	34.45%	37.82%	37.41%	44.17%	52.48%	53.46%	59.82%

Frequently Asked Questions About Encompass Health's Financials

When does Encompass Health's financial year end?

According to the most recent income statement we have on file, Encompass Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Encompass Health's net income changed over the last 9 years?

Encompass Health's net income appears to be on an upward trend, with a most recent value of $596.60 million in 2024, rising from $183.10 million in 2015. The previous period was $463 million in 2023. See where experts think Encompass Health is headed by visiting Encompass Health's forecast page.

What is Encompass Health's operating income?

Encompass Health's total operating income in 2024 was $864.50 million, based on the following breakdown:

Total Gross Profit: $2.41 billion
Total Operating Expenses: $1.55 billion

How has Encompass Health revenue changed over the last 9 years?

Over the last 9 years, Encompass Health's total revenue changed from $3.16 billion in 2015 to $5.37 billion in 2024, a change of 69.9%.

How much debt does Encompass Health have?

Encompass Health's total liabilities were at $3.69 billion at the end of 2024, a 3.1% decrease from 2023, and a 0.5% decrease since 2015.

How much cash does Encompass Health have?

In the past 9 years, Encompass Health's cash and equivalents has ranged from $21.80 million in 2022 to $224 million in 2020, and is currently $85.40 million as of their latest financial filing in 2024.

How has Encompass Health's book value per share changed over the last 8 years?

Over the last 8 years, Encompass Health's book value per share changed from 6.69 in 2015 to 20.52 in 2024, a change of 206.8%.

Related Companies

This page (NYSE:EHC) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Encompass Health (EHC) Financials

Frequently Asked Questions About Encompass Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Encompass Health (EHC) Financials

Annual Income Statements for Encompass Health

Quarterly Income Statements for Encompass Health

Annual Cash Flow Statements for Encompass Health

Quarterly Cash Flow Statements for Encompass Health

Annual Balance Sheets for Encompass Health

Quarterly Balance Sheets for Encompass Health

Annual Metrics And Ratios for Encompass Health

Quarterly Metrics And Ratios for Encompass Health

Frequently Asked Questions About Encompass Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools